A 58-year-old woman admitted to an outpatient department with erythematosus and mild itching on her right cheek for six months was reported. She had type 2 diabetes and was being treated with metformin and glimepiride. Her fasting blood sugar remained slightly high, fluctuating around 8.0 mmol/L. She reported no personal or family history of tuberculosis. Further investigation revealed that she had stable, fingernail-sized erythema on her right cheek for 20 years. It did not change until six months ago, and her facial lesions expanded significantly. Physical examination of her right cheek revealed erythema, papules, and slight desquamation (Figure 1). The patient said there had been pustules and exudation when the disease worsened early. A T-cell spot test of MTB showed positive. Skin biopsy histopathology showed mild epidermal hyperplasia, with several epithelial cell masses of different sizes in the superficial and deep dermis. Lymphocytes were infiltrated around, and the boundary was clear. Caseous necrosis was not observed (Figure 2A and B). Direct immunofluorescence test showed that IgG basal membrane was suspiciously weak positive (+-), and IgM, IgA, and C3 were negative (-). Findings on computed tomographic (CT) scan of her chest were normal. The positive colonies that grew on the Lowenstein-Jensen medium tissue sample inoculated after 35 days at 37 C were identified as MTB by PCR and DNA sequencing and acid-fast bacilli staining (Figure 3). And the tissue samples were also inoculated on the Sabouraud dextrose agar (SDA) plate at 28 C. The positive colonies that grew on the medium after ten days were identified as Candida albicans (Figure 4). Microscopic examination of the local erythema fungus on the face showed positive hypha. Although infection of the face is a rare extrapulmonary manifestation of tuberculosis, it is exceptional to have a concurrent infection with Candida albicans at the same site. It is an essential consideration for a patient with type 2 diabetes who has a history of poor glycemic control. Itraconazole 0.2 g bid was administered for seven days, and rifampicin 0.45 g qd, isoniazid tablet 0.3 g qd, and ethambutol hydrochloride 0.25 g tid were administered for five months (Figure 5).